Oct 2026
Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group.
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) has poor outcomes and high rates of locoregional recurrence. MASTERPLAN evaluated whether stereotactic body radiotherapy (SBRT) reduced locoregional recurrence in patients with high-risk, localised PDAC. METHODS MASTERPLAN was an open-label, randomised, phase 2 trial...
A. Oar, A. Kneebone, K. Sjoquist et al.
· The Lancet Oncology · 0 citations